
le #CANCER.fr site d'#ACTUALITÉ #santé scientifique en #ONCOLOGIE. #MÉDECINE #CLCC #CHU #CONGRÈS #CHIMIOTHÉRAPIE #IMMUNOTHÉRAPIE #oncology #ASCO #SABCS #ESMO
Paris
Joined May 2012
- Tweets5.2K
- Following131
- Followers1.4K
- Likes141
LeCancer.fr retweeted
Epuisant 😅 mais enthousiasmant 😁
Le groupe #CBNPC révise la version de travail du référentiel 2024 ##ARISTOT!
Une coopération des équipes d'oncologie thoracique des 4 CHU et 2 CLCC de @auvergnerhalpes.
@CHUdeLyon @ChuSaintEtienne @CHUClermontFd @CLCCLeonBerard
#NovembrePerle
LeCancer.fr retweeted
Bienvenu aux participants et partenaires de l’édition 2018 des référentiels AURA d’oncologie thoracique #refAURA18 #lyon
LeCancer.fr retweeted
Guidelines on thoracic cancers. 2017 edition #Lyon
LeCancer.fr retweeted
Que hagas RT no cura,cierto,pero visibiliza,sensibiliza,desdramatiza y hoy sirve de apoyo a #mujeres pacientes de #cáncerginecológico – at San Sebastián de los Reyes, España
LeCancer.fr retweeted
#JournéeEuropéennedelaProstate: le 20/09, l'AFU organise un chat Facebook pr tt savoir sur le cancer de la #prostate. Posez vos questions!
LeCancer.fr retweeted
ALK resistance overview in 2 slides #ESMO17
LeCancer.fr retweeted
The largest study to date of Immune-checkpoint inhibitors associated interstitial lung disease. #NSCLC #Melanoma erj.ersjournals.com/content/…
LeCancer.fr retweeted
another potential mechanism of resistance. RHOB confers resistance to EGFR-TKI in NSCLC via AKT. EMBO Mol Med. onlinelibrary.wiley.com/doi/…
LeCancer.fr retweeted
BRAF V600 NSCLC: combo dabra/trametinib the best deal for efficacy but take care to high toxicity (50% G3-4; 20% discontinuation for tox)
LeCancer.fr retweeted
#ESMO17 @Annals_Oncology immune targets to
enhance cancer immunotherapy Marabelle et al @GustaveRoussy doi.org/10.1093/annonc/mdx17…
LeCancer.fr retweeted
#ESMO17 better cns control with alectinib
LeCancer.fr retweeted
Don't forget: liquid biopsies are not only in blood ! @JulienMazieres
LeCancer.fr retweeted
Great review on clinical application of liquid biopsy for management of NSCLC by Dr Wang #ESMO17 #liquidgold #ctDNA
LeCancer.fr retweeted
Targetting FGFR is interesting in mesothelioma and well-tolerated. Looking forward further trials
LeCancer.fr retweeted
Pembro in #mesothelioma. Very nice results from the Swiss registry. Esp. in good PS, sarcomatoid & PDL1 pos tumors #esmo17




































